Unfortunately, more than 700 rare diseases affect more than 30 million people in the US alone and with many of them being life threatening, it is still a concern that most still do not have treatments.
As the year draws to a close, Outsourcing-Pharma caught up with some senior executives for a three-part series looking back on an eventful 2022, and look ahead to 2023.
As the year draws to a close, Outsourcing-Pharma caught up with some senior executives for a three-part series looking back on an eventful 2022, and look ahead to 2023.
The Lifebit CloudOS will be employed to create a Federate Trusted Research Environment within the center’s supercomputing cluster to handle data management.
A clinical trial logistics expert discusses specialized concerns involved in transporting cell and gene products and other personalized medicine items.
Lonza and Israel-based Sheba Medical collaborate to use the CDMO’s manufacturing platform for point-of-care genetically engineered human CAR-T cell production.
Lonza enters private label partnership to manufacture and globally commercialize AllCell’s hematopoietic primary cells to provide greater access to researchers.
With the recent marriage between technology and science aimed at innovating aspects of clinical trials panels composed of experts from fields outside of pharma could prove to be impactful.
The biopharma industry is on the precipice of making personalized medicine a reality with access to massive amounts of data, computing power, and artificial intelligence to run in silico clinical trials, says GNS Healthcare CEO.
Cryoport is supporting a record number of clinical trials driven by rapid growth in regenerative medicine – a space that will continue to grow and outpace the pharmaceutical industry, says CCO.
